Xanodyne Pharmaceuticals, Inc.
http://www.xanodyne.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Xanodyne Pharmaceuticals, Inc.
Finance Watch: Rivus Raises $132m In Series B Cash To Fund Obesity Drug Trials
VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.
Novartis Changing Of The Guard Continues As R&D Chief Bradner Exits
A smooth handover hints at an amicable departure for Jay Bradner, but also gives CEO Vas Narasimhan the chance to refresh strategy with a new team.
Deal Watch: Ovid Teams With Gensaic On Phage-Derived, Gene-Delivered Therapies
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
Genentech Licenses Prostate Cancer Drug From China-Based Jemincare
Deal Snapshot: Other major players have made headway in bispecifics for prostate cancer, while Jemincare’s drug is the latest China-developed technology to head westward.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals